This HTML5 document contains 113 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
n11	http://dx.doi.org/10.1093/RHEUMATOLOGY/
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q84873631

rdf:type

wikibase:Item

schema:description

artykuł naukowy vedecký článok სამეცნიერო სტატია artigo científico tudományos cikk научна статия научни чланак articol științific 2012 nî lūn-bûn scienca artikolo teaduslik artikkel 2012年学术文章 наукова стаття, опублікована в серпні 2012 article scientifique vitenskapelig artikkel επιστημονικό άρθρο 2012年学术文章 2012年學術文章 2012년 논문 tieteellinen artikkeli artigo científico scientific article published on 25 August 2012 videnskabelig artikel udgivet 25. august 2012 2012年學術文章 vetenskaplig artikel bilimsel makale מאמר מדעי 2012年学术文章 vitskapeleg artikkel artikulong pang-agham 2012年学术文章 scientific article published on 25 August 2012 artículu científicu ২৫ আগস্ট ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2012年學術文章 artikel ilmiah artigo científico научная статья wissenschaftlicher Artikel articolo scientifico 2012年の論文 vědecký článek bài báo khoa học 2012年学术文章 2012年学术文章 мақолаи илмӣ مقالة علمية نشرت في 25 أغسطس 2012 artículo científico publicado en 2012 wetenschappelijk artikel artikull shkencor научни чланак scientific article published on 25 August 2012 บทความทางวิทยาศาสตร์ article científic article scientific 2012年學術文章 2012年學術文章 naučni članak

p:P577

wds:Q84873631-EF4B9A45-A16F-45A4-9513-ED8AD55B46AA

wdt:P577

2012-08-25T00:00:00Z

p:P2093

wds:Q84873631-67B8E1BB-C97D-450B-BCF7-F4AEA99F97E2 wds:Q84873631-0A1A6F35-4A55-4FAF-B881-88AB0FEE6D94 wds:Q84873631-FC1636AD-050F-4208-A7D3-7EC6BBC7E05D wds:Q84873631-BBC1F98B-751D-4656-B381-40E5A8A3E191 wds:Q84873631-BF2F7C02-C72D-4CE7-9EE8-3EC4CA3EB8AD wds:Q84873631-8D63746E-B725-40F9-B0C5-3932DA7D82A8 wds:Q84873631-DFEAA3CD-1CA7-41EA-AFD9-02C485FABD86 wds:Q84873631-EB5038EB-DBD3-4ECF-B124-8581494A7DD3

wdt:P2093

Clifton O Bingham Elena M Massarotti Jürgen Wollenhaupt Ronald F van Vollenhoven Ben Duncan Owen R Davies Roy Fleischmann Maxime Dougados

rdfs:label

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

skos:prefLabel

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

schema:name

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

p:P50

wds:Q84873631-4FD2E927-435B-400E-8410-243E00DC24AB wds:Q84873631-637C79F8-9CF0-4D87-B4FF-ACDAEA6675FE wds:Q84873631-87EA1A54-CB08-4E6E-BF42-86A1DE6D6685 wds:Q84873631-B95B70E1-7C15-4345-B570-549BD9D9CAED wds:Q84873631-F8AB904D-8D6E-4249-8D54-2B80F5660006

wdt:P50

wd:Q88922582 wd:Q48742471 wd:Q19859634 wd:Q71634719 wd:Q77086497

p:P1476

wds:Q84873631-EE77EDF3-AF29-4663-A0D2-9AE239F866BB

wdt:P1476

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

p:P304

wds:Q84873631-042285F7-B666-452E-B32F-0CE5DA0D8170

wdt:P304

2204-2214

p:P31

wds:Q84873631-7121A04C-6D8D-4A21-B2D6-F0D3F1732DB1

wdt:P31

wd:Q13442814

p:P921

wds:Q84873631-83D967FE-1046-4FAA-8883-6A1D05ABAAF9

wdt:P921

wd:Q187255

p:P698

wds:Q84873631-6D926EDD-6686-43FE-8209-44FB4936A945

wdtn:P698

n12:22923753

wdt:P698

22923753

p:P1433

wds:Q84873631-2DC42599-9A78-4F63-A3EF-DB648B9FD5B3

wdt:P1433

wd:Q7320492

p:P433

wds:Q84873631-2C05A2B9-563B-4D3A-A863-A7AC2FFC97C4

p:P478

wds:Q84873631-C9CC3132-E547-42D7-83D2-E62505766E62

wdt:P433

12

wdt:P478

51

p:P356

wds:Q84873631-D3972493-F5B7-49EF-91CE-5864FEFEEC4F

wdtn:P356

n11:KES150

wdt:P356

10.1093/RHEUMATOLOGY/KES150